Navigation Links
Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDF's 20th World Diabetes Congress
Date:10/21/2009

For Early or New-Onset Type 1 Diabetes) is a randomized, placebo-controlled Phase 3 trial intended to enroll approximately 240 patients, age 12 to 45, with newly diagnosed autoimmune type 1 diabetes. DEFEND is being conducted at over 100 study centers throughout Europe and North America. The trial is designed to evaluate whether a single course of otelixizumab, administered not more than 90 days after the initial diagnosis of autoimmune type 1 diabetes, will preserve beta cell function as measured by C-peptide, a surrogate measure of beta cell function. The primary endpoint will be a measurement of C-peptide. For information about DEFEND, please visit www.DefendAgainstDiabetes.com.

About the TTEDD Study

TTEDD is a non-randomized, open-label Phase 2 study intended to enroll approximately 100 patients, age 18 to 45, with autoimmune type 1 diabetes. The purpose of TTEDD is to optimize several multi-dose regimens of otelixizumab, determine the highest biologically active dose, evaluate biomarkers and surrogates of efficacy, and to evaluate the effects of each multi-dose regimen of otelixizumab against standard safety and efficacy parameters.

About Type 1 Diabetes

Diabetes (medically known as diabetes mellitus) is the name given to disorders in which the body has difficulty regulating its blood glucose (sugar) level. There are two major types of diabetes: type 1 and type 2. Type 1, previously known as juvenile diabetes or insulin-dependent diabetes, is a disorder of the body's immune system. In type 1 diabetes, the immune system attacks and destroys the insulin-producing beta cells in the pancreas. As a result of the decrease in endogenous (natural) insulin production, patients must monitor their glucose levels frequently and administer insulin regularly to control their blood glucose levels.

About Otelixizumab'/>"/>

SOURCE Tolerx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Tolerx Announces Amendment to Phase 3 DEFEND Protocol
2. Tolerx Expands Phase 3 DEFEND Trial of Otelixizumab in Europe
3. Laureate Announces Manufacturing Agreement with Tolerx
4. Tolerx Named as One of the Fierce 15 Biotech Companies of 2008
5. Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31, 2009
6. AlphaHelix Presents AmpXpress(TM) at the BIOTECHNICA Show
7. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
8. InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
9. NovaBay(R) Presents Data Confirming Its Aganocide(R) Compounds Are Effective In Killing Bacteria That Have Developed Multidrug-Resistance
10. Novexel Presents 16 Posters and one Slide Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in San Francisco
11. Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... - SQI Diagnostics Inc. (TSX-V: SQD), a life sciences company ... advanced microarray diagnostics, today announced it will hold an ... pm ET.  During the call, ... of SQI,s recent commercialization progress and then introduce Dr. ... appointed to the Board of Directors of SQI and ...
(Date:8/18/2014)... YORK , August 18, 2014 ... published by Transparency Market Research "Life Science Reagents ... Flow Cytometry, Electrophoresis, Chromatography, In-Vitro Diagnostic Reagents and ... and Academic Institutions, Clinical Laboratories, and Forensic Laboratories)- ... Forecast, 2013 - 2019", the global life science ...
(Date:8/18/2014)... 18. August 2014 Vier führende ... internationale klinische Studie auf, in der eine ... soll das Sehvermögen bei allen Entfernungen verbessern, ... möglicherweise keine Lese- oder Gleitsichtbrille mehr benötigen. ... FluidVision Accommodating Intraocular Lens (FluidVision ...
(Date:8/15/2014)... FOREST, Ill. , Aug. 15, 2014   ... world,s leading provider of injectable drugs and infusion technologies, ... Morgan Stanley Global Healthcare Conference on Tuesday, Sept. 9, ... The presentation is scheduled to begin at 11:45 ... will be available to all interested parties through a ...
Breaking Biology Technology:SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4
... when theoretical work is eventually supported by experimentation. Such ... Italian and US scientists when they received preliminary confirmation ... that is currently orbiting the Earth on the Foton-M3 ... week ago, the scientists are already very excited about ...
... Board Reflects Emphasis on Drug Development and Recent ... ... Lexicon,Pharmaceuticals, Inc. (Nasdaq: LXRX ) announced several changes to ... drug development and the completion of a major strategic financing,with ...
... NanoBio(R) Corporation, a,biopharmaceutical company developing novel anti-infective ... infections, today announced,the addition of four new scientists ... PharmD, Ph.D.; Susan Ciotti, Ph.D.; Robert L. Hagan, ... developing and commercializing,its novel topical anti-infectives and mucosal ...
Cached Biology Technology:Fluid theory confirmed by Foton 2Lexicon Appoints Judith Swain, M.D. to Board of Directors 2Lexicon Appoints Judith Swain, M.D. to Board of Directors 3Lexicon Appoints Judith Swain, M.D. to Board of Directors 4NanoBio Expands Drug Development Team for Its Anti-Infective Products 2NanoBio Expands Drug Development Team for Its Anti-Infective Products 3
(Date:8/19/2014)... Aug. 19, 2014 To improve students, chances ... grades, the University of Houston (UH) implemented a ... students at risk for failure. , Through ... Board (THECB), the Department of Biology and Biochemistry ... students taking "General Biology" for non-majors and "Introductory ...
(Date:8/19/2014)... is available in German . ... intermittent energy sources. If a large amount of electricity is ... excess energy will have to be stored during productive periods ... storage capacities are far from adequate for the purpose. Science ... important focus lies on battery systems that used to be ...
(Date:8/19/2014)... lemur. It,s not an African Bush Baby or even a ... downright "cool" primate from Southeast Asia. , "It,s really not ... Brown, curator-in-charge at the University of Kansas, Biodiversity Institute. "A ... body; a long tail with a furry tuft at the ... a bit like the disks on the digits of tree ...
Breaking Biology News(10 mins):University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3
... by global warming can prove extremely destructive to island habitats, ... C. Bellard, C. Leclerc and F. Courchamp of the ... possible scenarios, from optimistic to very pessimistic, to bring attention ... biodiversity hotspots worldwide. The study was published in the open ...
... measures carbon dioxide and suggests that far from being a ... a biological signalling molecule. Researchers led by Professor Nick ... of Warwick have shown that the body senses carbon dioxide ... receptor for the gas. Connexin 26 is better known as ...
... largest lake in Britain and Ireland, Lough Neagh, has lost ... to researchers at Queen,s University Belfast., The study by Quercus, ... number of diving ducks migrating to the lake for the ... in the space of a decade., The research, published in ...
Cached Biology News:Island biodiversity in danger of total submersion with climate change 2Carbon dioxide's new-found signalling role could be applied to blood flow, birth and deafness 2Largest lake in Britain and Ireland has lost three-quarters of winter water birds 2
5-bromouridine 5'-triphosphate (BrUTP) *10 mM in TE buffer*...
...
in vitro Translation, Accessory Products...
... The GenoStat Inducible Expression System provides tightly ... mammalian cells and is capable of repeated ... is mediated by the highly specific interaction ... bipartite nuclear receptor complex. Gene expression levels ...
Biology Products: